C1q/TNF-related protein 1 promotes endothelial barrier dysfunction under disturbed flow

• DOI: 10.1016/j.bbrc.2017.06.081
• Publication Date: 2017-06-16T11:46:25Z
• Authors: Zhu Hui Liu; Chang Li; Jia Wei Chen; Ying Shen; Jie Gao; Wei Feng Shen; Rui Yan Zhang; Xiao Qun Wang; Lin Lu
• Keywords: Mice, Knockout; 0301 basic medicine; Endothelial Cells; Proteins; Vascular Endothelial Growth Factor Receptor-2; Capillary Permeability; 03 medical and health sciences; Adipokines; Human Umbilical Vein Endothelial Cells; Animals; Endothelium, Vascular; Gene Knock-In Techniques; Aorta; Blood Flow Velocity

Endothelial hyper-permeability is a major determinant factor that contributes to the accelerated development of atherosclerotic lesions at hemodynamically disturbed sites. Previously, we showed that C1q/TNF related protein (CTRP) 1 promotes endothelium-leukocyte interactions and inflammatory responses in vascular cells. Here, we sought to investigate the role of CTRP1 in modulation of endothelial permeability under disturbed flow condition. By using en face staining of mouse aorta, we found CTRP1 expression was significantly increased in vascular endothelial cells under disturbed flow as compared to steady laminar flow. Vascular permeability to Evans blue dye was notably enhanced in CTRP1 knockin mice as compared to wild type animals, whereas aortic hyper-permeability at disturbed sites was remarkably restored after deletion of CTRP1. In cultured endothelial cells, treatment of CTRP1 led to increased permeability to fluorescent-labelled dextran and apparent formation of paracellular holes as observed after disturbed flow exposure, which was evidently reduced in the presence of a CTRP1-specific neutralizing antibody. Mechanistically, we found activation of VEGFR2 by CTRP1 might be involved in vascular hyper-permeability under disturbed flow condition. Taken together, this study suggests that CTRP1 is a mechano-sensitive proinflammatory factor that mediates disturbed flow-induced vascular barrier dysfunction. Inhibition of CTRP1 may inhibit the pathogenesis of atherosclerosis at early stage.